Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S. Stein EM, et al. Among authors: risueno a. Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3. Blood. 2019. PMID: 30510081 Free PMC article. Clinical Trial.
DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling.
Campos-Laborie FJ, Risueño A, Ortiz-Estévez M, Rosón-Burgo B, Droste C, Fontanillo C, Loos R, Sánchez-Santos JM, Trotter MW, De Las Rivas J. Campos-Laborie FJ, et al. Among authors: risueno a. Bioinformatics. 2019 Oct 1;35(19):3651-3662. doi: 10.1093/bioinformatics/btz148. Bioinformatics. 2019. PMID: 30824909 Free PMC article.
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. O'Connor OA, et al. Among authors: risueno a. Blood. 2019 Oct 24;134(17):1395-1405. doi: 10.1182/blood.2019001285. Blood. 2019. PMID: 31471376 Free article. Clinical Trial.
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Carpio C, et al. Among authors: risueno a. Blood. 2020 Mar 26;135(13):996-1007. doi: 10.1182/blood.2019002395. Blood. 2020. PMID: 31977002 Free PMC article.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne B, Zhong J, Beach CL, Risueño A, Menezes DL, Ossenkoppele G, Döhner H. Roboz GJ, et al. Among authors: risueno a. Blood. 2022 Apr 7;139(14):2145-2155. doi: 10.1182/blood.2021013404. Blood. 2022. PMID: 34995344 Free article. Clinical Trial.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Döhner H, et al. Among authors: risueno a. Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293. Blood. 2022. PMID: 35960871 Free PMC article. Clinical Trial.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L. Levy BP, et al. Among authors: risueno a. Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30654297 Clinical Trial.
24 results